We identified an important role of endothelial miR‐21‐DDAH1‐ADMA‐eNOS‐NO signalling in DMY‐ameliorated atherosclerotic lesion formation, indicating that DMY supplementation may serve as a potential therapeutic adjuvant for treating atherosclerosis. Here, DDAH1 is linked to atherosclerosis.